Novartis International AG - Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL

- 4 Décembre 2016

Novartis International AG / Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible...

Source : http://www.romandie.com/news/Novartis-Internationa...

Dans la même rubrique :

Novartis International AG - Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL

{{date}} {{title}}